Comment from BioinvestGPT ApS

Summary: BioinvestGPT ApS, a pharmaceutical technology company, supports the FDA's drug repurposing initiative and proposes integrating its mechanistic AI tool (BVCT) into the regulatory workflow. They argue that their tool provides a platform-neutral, patient-data-free method for prioritizing drug candidates and cross-checking evidence-driven results.